Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

iBio (IBIO) EBIT (2016 - 2025)

iBio (IBIO) has disclosed EBIT for 16 consecutive years, with -$9.4 million as the latest value for Q4 2025.

  • Quarterly EBIT fell 113.74% to -$9.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$25.5 million through Dec 2025, down 63.71% year-over-year, with the annual reading at -$18.6 million for FY2025, 11.83% down from the prior year.
  • EBIT for Q4 2025 was -$9.4 million at iBio, down from -$6.0 million in the prior quarter.
  • The five-year high for EBIT was -$3.4 million in Q2 2024, with the low at -$10.6 million in Q4 2022.
  • Average EBIT over 5 years is -$6.3 million, with a median of -$5.6 million recorded in 2021.
  • The sharpest move saw EBIT plummeted 222.26% in 2021, then skyrocketed 57.48% in 2023.
  • Over 5 years, EBIT stood at -$7.2 million in 2021, then crashed by 46.22% to -$10.6 million in 2022, then surged by 57.48% to -$4.5 million in 2023, then rose by 1.71% to -$4.4 million in 2024, then tumbled by 113.74% to -$9.4 million in 2025.
  • According to Business Quant data, EBIT over the past three periods came in at -$9.4 million, -$6.0 million, and -$5.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.